Brief: IGC Pharma Announces Patient Enrollment At Neurostudies In Phase 2 Trial Investigating Igc-Ad1
28/05/2024 14:15
May 28 (Reuters) - IGC Pharma Inc IGC.A :
* IGC PHARMA ANNOUNCES PATIENT ENROLLMENT AT NEUROSTUDIES IN
PHASE
2 TRIAL INVESTIGATING IGC-AD1
* IGC PHARMA INC -ADVANCING IGC-AD1 TOWARD COMMERCIALIZATION
AS A
TREATMENT FOR AGITATION IN ALZHEIMER'S
Source text for Eikon: ID:nBw81JkrKa
Further company coverage: IGC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IGC Pharma
See all newsFocus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Cannabis stocks climb after Trump signs order to ease curbs on marijuana (updated)
Cannabis stocks rise ahead of potential Trump order to ease marijuana restrictions
Brief: IGC Pharma's Unit Enters Sale Of Assets Agreement For $2.7 Million - SEC Filing
Brief: IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment